Iterum Therapeutics Plc
Understanding the Risks of Investing in Iterum Therapeutics Plc (ITRM)
Iterum Therapeutics Plc’s filing revealed that its Director Dunne Michael W. acquired Company’s shares for reported $2191.0 on Nov 18 ...
Investing in Iterum Therapeutics Plc (ITRM): What You Must Know
Iterum Therapeutics Plc’s filing revealed that its Director Dunne Michael W. acquired Company’s shares for reported $2191.0 on Nov 18 ...
Gabelli & Co gives a Hold recommendation for Iterum Therapeutics Plc (ITRM)
Iterum Therapeutics Plc’s recent filing unveils that its Director Dunne Michael W. acquired Company’s shares for reported $2191.0 on Nov ...
An Analysis of Iterum Therapeutics Plc (ITRM)’s Potential Price Growth
In a filing, Iterum Therapeutics Plc revealed its Director Dunne Michael W. acquired Company’s shares for reported $2191.0 on Nov ...
Iterum Therapeutics Plc [ITRM] Stock bought by Insider Dunne Michael W. for $10854.0
Iterum Therapeutics Plc’s recent filing unveils that its Director Dunne Michael W. acquired Company’s shares for reported $10854.0 on Aug ...
ITRM stock rated a Hold by Gabelli & Co
Iterum Therapeutics Plc’s filing revealed that its Director Dunne Michael W. acquired Company’s shares for reported $10854.0 on Aug 08 ...
ITRM’s latest rating updates from top analysts.
In a filing, Iterum Therapeutics Plc revealed its Director Dunne Michael W. acquired Company’s shares for reported $10854.0 on Aug ...
Iterum Therapeutics Plc (ITRM) receives a Hold rating from Gabelli & Co
Iterum Therapeutics Plc’s recent filing unveils that its Director Dunne Michael W. acquired Company’s shares for reported $10854.0 on Aug ...
